Aptagen, LLC
DNA
Plasminogen Activator Inhibitor-1
Protein
339 pM (reported value)
PBSMCT (DPBS with 2.5 mM MgCl2, 1 mM CaCl2, 0.05% TWEEN-20)
23°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
PAI-1 01 (ID# 612)
5'dCpdApdTpdTpdGpdApdGpdApdTpdApdGpdCpdTpdApdGpdTpdTpdGpdTpdApdGpdCpdTpdGpdCpdGpdTpdCpdApdTpdApdGpdGpdCpdTpdGpdGpdGpdTpdTpdGpdGpdGpdTpdCpdTpdApdGpdTpdGpdGpdTpdTpdGpdGpdGpdTpdGpdTpdGp3'
60
18766.23 g/mole
579300 L/(mole·cm)
51.67%
1.73
32.39
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Wang, J., Gong, Q., Maheshwari, N., Eisenstein, M., Luz Arcila, M., Kosik, K., & Soh, T. Particle Display: A Quantitative Screening Method for Generating High-Affinity Aptamers. Angew. Chem. Int. Ed. 2014, 53, 4796ƒ??4801
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.